No Detail Found!

Current practices of urologists regarding intravesical therapy use for non-muscle- invasive bladder cancer patients.

Author(s)
Muhammad Farhan Urology Department, Abbasi Shaheed Hospital,Karachi-,Pakistan
Syed Farhan Ahmed Urology Department, Liaquat National Hospital, Karachi-Pakistan.
Hammad Mithani Urology Department, Dow University of Health Sciences, Karachi-Pakistan.
Wajahat Aziz Urology Department, Aga Khan University Hospital, Karachi-Pakistan.
Syed Muhammad Nazim Urology Department, Aga Khan University Hospital, Karachi-Pakistan.
Muhammad Khurram Zia Surgery Department, Liaquat College of Medicine and Dentistry,Karachi-,Pakistan
Abstract
Background: Intravesical chemotherapy and immunotherapy is recommended as per the leading urology treatment guidelines of non-muscle invasive bladder cancer (NMIBC). These therapies also help in reducing the risk of progression and recurrence of NMIBC. The current study aims to assess the self-reported practices regarding intravesical therapy (IVT) used for NMIBC patients among urologists in Karachi. Methodology: In this cross-sectional study, a proforma-based survey was conducted between January and March 2018, in which printed questionnaires regarding adjuvant treatment options for NMIBC were administered and collected by primary investigators by urologists in leading institutions of Karachi. Results: It is observed that routine administration of single instillation of intravesical chemotherapy (SICA) after transurethral resection of bladder tumor (TURBT) was reported by 80% of the respondents, and almost one-third of them (37.3%) give SICA within 6 hours inward. A quarter of respondents practice induction therapy routinely in low-risk BC using Mitomycin, whereas Bacillus Calmette Geurin (BCG) as immunotherapy was used in 76.5% of high-risk cases. Regarding the time interval of intravesical therapy installation, most of the urologists reported for 45 mins (49%) followed by 30 mins (29.4%), 2 hrs (17.6%), and 3 hrs (3.9%). Maintenance therapy with BCG for high-risk BC was used by only 39% of urologists. While 76.5% of participants reported the use of radical cystectomy, as the failure of BCG. Conclusion: Our survey results provide evidence of variation in practices by urologists and also highlight the poor guideline along with the risk of under-treatment of NMIBC patients. Therefore, joint efforts of all concerned individuals are needed who are involved in the treatment of NMIBC to improve the quality of care.
Publication Details
Page(s) 72-77
Published Journal: International Journal of Endorsing Health Science Research, Volume: 10, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Chemotherapy, Practices, Immunotherapy, Intravesical, Bladder cancer, NonInvasive
0

Citations

0

Downloads

87

Views